Clinical Trials Logo

Shift-Work Sleep Disorder clinical trials

View clinical trials related to Shift-Work Sleep Disorder.

Filter by:

NCT ID: NCT00688142 Completed - Clinical trials for Shift Work Sleep Disorder

Sleepiness and Brain Function: The Effect of Armodafinil in Shift Work Sleep Disorder

Start date: February 2008
Phase: N/A
Study type: Observational

The investigators hypothesize that in patients with shift work sleep disorder, armodafinil will specifically increase brain activity in the frontal cortex parallel with improvements in deficits of fundamental mechanisms of attention.

NCT ID: NCT00080288 Completed - Clinical trials for Excessive Sleepiness

Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD

Start date: March 2004
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with chronic shift work sleep disorder (SWSD) by measuring mean sleep latency from the Multiple Sleep Latency Test (MSLT) (20 minutes) (average of 4 naps at 0200, 0400, 0600, and 0800) and by Clinical Global Impression of Change (CGI-C) ratings.

NCT ID: NCT00078312 Completed - Clinical trials for Sleep Apnea, Obstructive

Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder

Start date: January 2004
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of Armodafinil (CEP-10953) administered on a flexible-dosage regimen of 100 to 250 mg/day for up to 12 months to patients with excessive sleepiness associated with a current diagnosis of narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS)(regular users of nasal continuous positive airway pressure [nCPAP] therapy), or chronic shift work sleep disorder (SWSD).